Breaking News Instant updates and real-time market news.

AMGN

Amgen

$192.33

3.05 (1.61%)

16:36
01/22/18
01/22
16:36
01/22/18
16:36

Amgen: Aimovig met all primary, secondary endpoints in Phase 3b LIBERTY study

Amgen announced positive results from the Phase 3b LIBERTY study assessing the efficacy and safety of Aimovig 140 mg in patients with episodic migraine who had experienced two to four previous preventive treatment failures, due to lack of efficacy or intolerable side effects. The study met its primary endpoint, with significantly more patients taking Aimovig experiencing at least a 50% reduction from baseline in their monthly migraine days as compared to placebo. LIBERTY also met all secondary endpoints, including reduction of monthly migraine days, reduction in days needing acute (rescue) medication, improvement in scores on the Migraine Physical Function Impact Diary tool, and 75% and 100% responder rates (number of patients experiencing at least a 75% or 100% reduction in monthly migraine days compared to placebo). The safety data are consistent with previous studies of Aimovig to date. Full data will be presented at an upcoming scientific meeting. The safety, efficacy and tolerability of Aimovig have been assessed in more than 3,000 patients, including an ongoing open-label extension of up to five years in duration. Aimovig was the first investigational therapy targeting the CGRP pathway to receive U.S. FDA and European Medicines Agency regulatory filing acceptance. The FDA has set a Prescription Drug User Fee Act target action date of May 17, 2018. If approved, it will be administered once-monthly using a self-injection device. If approved, Novartis and Amgen will co-commercialize Aimovig in the U.S. Amgen has exclusive commercialization rights to the drug in Japan and Novartis has exclusive rights to commercialize in rest of world.

  • 25

    Jan

  • 03

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 23

    Apr

  • 30

    Apr

  • 17

    May

  • 28

    May

AMGN Amgen
$192.33

3.05 (1.61%)

12/18/17
MSCO
12/18/17
NO CHANGE
MSCO
Morgan Stanley sees opportunities in biotech amid 'limited' investor conviction
With clinical catalysts in large-cap Biotechnology limited to only five key Phase III readouts - three of which are from Alexion (ALXN) - investors are describing their 2018 picks in the space as the "least worst" of the group, according to Morgan Stanley analyst Matthew Harrison. However, he believes this lack of conviction creates real opportunity for outsized moves in 2018, with Amgen (AMGN) identified by Harrison as the biggest potential beneficiary of M&A given "its likely newfound access" to about $39B in offshore cash. Other biotech names the analyst highlights on the up side include Biogen (BIIB), BioMarin (BMRN), Biohaven (BHVN) and Sarepta (SRPT). Meanwhile, Harrison highlights his concerns about potential downside for BioVerativ (BIVV) and Innoviva (INVA), on both of which he keeps Underweight ratings.
12/29/17
PIPR
12/29/17
NO CHANGE
PIPR
Biotech fund outflows continue, says Piper Jaffray
For the weekly period ending Wednesday, December 27, healthcare/biotech funds saw $338M in net outflows, representing a 0.58% decrease in assets, Piper Jaffray analyst Christopher Raymond tells investors in a research note. This marks the seventh straight negative week and the eleventh week of outflows in the past 12 weeks, the analyst points out in a research note titled "Ending 2017 on a Down Note: Biotech Outflows Continue."
01/02/18
PIPR
01/02/18
NO CHANGE
PIPR
Overweight
Piper highlights 'clockwork' drug price increases by Amgen, Biogen
Amgen (AMGN) and Biogen (BIIB) took price increases on a number of important franchise products effective January 1, 2018, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "'Tis the Season; Price Increases Continue Like Clockwork for Many Biotech Drugs." While political scrutiny of drug pricing tactics "may come and go," demand for dominant biologics and specialty therapies with truly differentiated profiles appears to remain relatively price inelastic, Raymond contends. He notes that Amgen raised Enbrel's price by 9.7% and Neulasta's price by 5%. Biogen raised Tecfidera's price by 8%, Avonex/Plegridy's price by 8% and Tysabri's price by 3%, the analyst notes, citing data from Wolters Kluwer Heath. Raymond keeps Overweight ratings on both Amgen and Biogen.
01/02/18
PIPR
01/02/18
NO CHANGE
PIPR
Overweight
AbbVie joining peers with typical January price hikes, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss noted that AbbVie (ABBV) took early-January price increases, highlighting that Humira saw a 9.7% increase that is similar in both timing and magnitude to last year's increase and once again "exactly" matches Amgen's (AMGN) Enbrel. In a note of his own earlier this morning titled "'Tis the Season; Price Increases Continue Like Clockwork for Many Biotech Drugs," Piper Jaffray analyst Christopher Raymond highlighted that Amgen and Biogen (BIIB) also increased prices on a number of important franchise products effective January 1, 2018. Purkiss maintains his Overweight rating on AbbVie shares.

TODAY'S FREE FLY STORIES

CCB

Coastal Financial

$0.00

(0.00%)

21:11
07/17/18
07/17
21:11
07/17/18
21:11
Syndicate
Coastal Financial 2.85M share IPO priced at $14.50 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CRNX

Crinetics

$0.00

(0.00%)

21:08
07/17/18
07/17
21:08
07/17/18
21:08
Syndicate
Crinetics 6M share IPO priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

NSTG

NanoString

$12.74

-2.36 (-15.63%)

21:07
07/17/18
07/17
21:07
07/17/18
21:07
Syndicate
NanoString 4M share Secondary priced at $12.50 »

JPMorgan and UBS acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

  • 18

    Jul

ALV

Autoliv

$106.86

1.57 (1.49%)

21:06
07/17/18
07/17
21:06
07/17/18
21:06
Downgrade
Autoliv rating change  »

Autoliv downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$131.71

3.58 (2.79%)

21:06
07/17/18
07/17
21:06
07/17/18
21:06
Downgrade
Visteon rating change  »

Visteon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 07

    Aug

ABT

Abbott

$62.84

1.05 (1.70%)

, MS

Morgan Stanley

$49.20

0.29 (0.59%)

20:25
07/17/18
07/17
20:25
07/17/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ABT

Abbott

$62.84

1.05 (1.70%)

MS

Morgan Stanley

$49.20

0.29 (0.59%)

USB

U.S. Bancorp

$51.29

-0.01 (-0.02%)

TXT

Textron

$66.81

0.14 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

ADTN

Adtran

$16.05

0.1 (0.63%)

20:14
07/17/18
07/17
20:14
07/17/18
20:14
Earnings
Adtran reports Q2 adjusted EPS (10c), two estimates (32c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

FSBW

FS Bancorp

$61.64

-1.86 (-2.93%)

, ANCB

Anchor Bancorp

$28.50

0.3 (1.06%)

20:09
07/17/18
07/17
20:09
07/17/18
20:09
Hot Stocks
FS Bancorp to merge with Anchor Bancorp in $77M deal »

FS Bancorp (FSBW) and…

FSBW

FS Bancorp

$61.64

-1.86 (-2.93%)

ANCB

Anchor Bancorp

$28.50

0.3 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$26.41

-1.19 (-4.31%)

20:06
07/17/18
07/17
20:06
07/17/18
20:06
Hot Stocks
Breaking Hot Stocks news story on Canopy Growth  »

Greenstar Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$356.95

0.94 (0.26%)

19:10
07/17/18
07/17
19:10
07/17/18
19:10
Hot Stocks
Boeing awarded $3.9B government contract »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MRTN

Marten Transport

$22.10

(0.00%)

, UAL

United Continental

$72.66

0.38 (0.53%)

19:03
07/17/18
07/17
19:03
07/17/18
19:03
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Martin…

MRTN

Marten Transport

$22.10

(0.00%)

UAL

United Continental

$72.66

0.38 (0.53%)

CSX

CSX

$64.42

0.46 (0.72%)

MLNX

Mellanox

$84.85

0.9 (1.07%)

IBKR

Interactive Brokers

$64.65

1.93 (3.08%)

HCSG

Healthcare Services

$42.38

-0.3297 (-0.77%)

TXN

Texas Instruments

$115.80

1.21 (1.06%)

SAH

Sonic Automotive

$20.45

0.3 (1.49%)

CARA

Cara Therapeutics

$21.60

0.435 (2.06%)

CASI

Casi Pharmaceuticals

$7.26

-0.215 (-2.88%)

TLYS

Tilly's

$15.35

0.21 (1.39%)

CLX

Clorox

$135.00

0.71 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 18

    Jul

  • 18

    Jul

  • 24

    Jul

  • 02

    Aug

  • 26

    Aug

  • 19

    Jul

BHP

BHP Billiton

$48.73

0.24 (0.49%)

18:38
07/17/18
07/17
18:38
07/17/18
18:38
Hot Stocks
BHP Billiton sees FY19 copper equivalent output broadly in line with FY18 »

Says expects to achieve…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHP

BHP Billiton

$48.73

0.24 (0.49%)

18:35
07/17/18
07/17
18:35
07/17/18
18:35
Hot Stocks
BHP Billiton reports Q4 petroleum production 49 MMBOE, down 6% »

Reports Q4 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLX

Clorox

$135.00

0.71 (0.53%)

18:31
07/17/18
07/17
18:31
07/17/18
18:31
Downgrade
Clorox rating change at Goldman Sachs »

Clorox downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

NCS

NCI Building

$20.70

0.15 (0.73%)

18:27
07/17/18
07/17
18:27
07/17/18
18:27
Hot Stocks
NCI Building Systems, Ply Gem Parent to combine in stock-for-stock merger »

NCI Building Systems and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMX

America Movil, also tag AMOV

$17.39

-0.35 (-1.97%)

, AMOV

America Movil, also tag AMX

$17.45

-0.19 (-1.08%)

18:16
07/17/18
07/17
18:16
07/17/18
18:16
Earnings
America Movil reports Q2 operating profit MXN32.6M, up 4.8% from last year »

Reports Q2 revenue…

AMX

America Movil, also tag AMOV

$17.39

-0.35 (-1.97%)

AMOV

America Movil, also tag AMX

$17.45

-0.19 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,844.00

21.98 (1.21%)

18:08
07/17/18
07/17
18:08
07/17/18
18:08
Recommendations
Amazon.com analyst commentary at Piper Jaffray »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Jul

  • 16

    Aug

BRK.A

Berkshire Hathaway

$288,482.00

-1118 (-0.39%)

, BRK.B

Berkshire Hathaway

$190.47

-1.52 (-0.79%)

18:06
07/17/18
07/17
18:06
07/17/18
18:06
Hot Stocks
Berkshire Hathaway amends share repurchase program »

The Board of Directors of…

BRK.A

Berkshire Hathaway

$288,482.00

-1118 (-0.39%)

BRK.B

Berkshire Hathaway

$190.47

-1.52 (-0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNFP

Pinnacle Financial

$60.10

-0.5 (-0.83%)

18:02
07/17/18
07/17
18:02
07/17/18
18:02
Earnings
Pinnacle Financial reports Q2 EPS $1.15, consensus $1.14 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Sep

CHDN

Churchill Downs

$304.60

1.1 (0.36%)

18:02
07/17/18
07/17
18:02
07/17/18
18:02
Hot Stocks
Churchill Downs receives approval to increase historical racing machines »

Churchill Downs announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

CE

Celanese

$110.22

1.6 (1.47%)

18:01
07/17/18
07/17
18:01
07/17/18
18:01
Hot Stocks
Celanese announces acetic acid price increases in Asia »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

BLK

BlackRock

$504.89

1.14 (0.23%)

17:51
07/17/18
07/17
17:51
07/17/18
17:51
Hot Stocks
BlackRock raises quarterly dividend to $3.13 from $2.88 per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRNA

Dicerna

$12.47

0.57 (4.79%)

17:45
07/17/18
07/17
17:45
07/17/18
17:45
Conference/Events
Dicerna management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

GOOG

Alphabet

$1,198.81

14.57 (1.23%)

, GOOGL

Alphabet Class A

$1,213.65

17.07 (1.43%)

17:44
07/17/18
07/17
17:44
07/17/18
17:44
Periodicals
Google faces record EU fine over Android dominance, FT reports »

Alphabet's Google…

GOOG

Alphabet

$1,198.81

14.57 (1.23%)

GOOGL

Alphabet Class A

$1,213.65

17.07 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 23

    Jul

  • 23

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

BA

Boeing

$356.95

0.94 (0.26%)

17:39
07/17/18
07/17
17:39
07/17/18
17:39
Periodicals
Breaking Periodicals news story on Boeing »

Boeing awarded $3.9B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.